Precision BioSciences Announces Allowance of Fourth U.S. Patent Related to Engineered Meganucleases

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a Notice of Allowance for U.S. Patent Application 13/246,380 (“the ‘380 Application”). The allowed claims relate to an array of genome engineering methods, including the use of certain engineered meganucleases in plant cells. These methods encompass a key facet of Precision’s DNE genome engineering technology.

MORE ON THIS TOPIC